Clinical analysis of nasopharyngeal carcinoma

Abstract

Chemoradiotherapy is the main treatment modality for nasopharyngeal carcinoma because it is anatomically difficult to perform surgical therapy. In this study, we retrospectively reviewed 28 cases with nasopharyngeal carcinoma （NPC） who were treated with chemoradiotherapy （alternating chemoradiotherapy or concurrent chemoradiotherapy） in our department between 2001 and 2015.
Therapeutic effect, outcome-survival rate, treatment completion rate, adverse effects, and prognostic factors were evaluated. The five-year overall survival rate was 62％ and the cause-specific five-year survival rate was 73％ for the alternating chemoradiotherapy group. No independent prognostic factors for the treatment of nasopharyngeal carcinoma were identified in our study.
We concluded that alternating chemoradiotherapy is a useful treatment for nasopharyngeal carcinoma because of its good therapeutic effects.